Antiviral & Antimicrobial Countermeasures Discovery and Development Core

抗病毒物质

基本信息

批准号：
10793955
负责人：
Colleen B Jonsson
金额：
$ 121.61万
依托单位：
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-18 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10793955
关键词：
Abbreviations Animal Model Award Biomedical Research Communication Consumption Containment Development Drug Exposure Educational workshop Equipment Funding Goals Histology Human Image Immunohistochemistry In Vitro Infection Laboratories Maintenance Manuals Mass Spectrum Analysis Mission Paraffin Embedding Paraffin Tissue Pharmaceutical Preparations Pharmacodynamics Phase Procedures Process RNA Viruses Research Services Site Specialist Targeted Research Therapeutic Time Tissues Training Vendor Viral Work X-Ray Computed Tomography animal tissue antimicrobial drug development drug discovery efficacy study experience good laboratory practice imaging modality improved in vivo infectious disease model instrument instrumentation laboratory facility liquid chromatography mass spectrometry operation pathogen pre-clinical assessment preclinical development promote resilience prophylactic screening small molecule

项目摘要

PROJECT ABSTRACT The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development of countermeasures for prophylactic or therapeutic treatment of human biosafety level 3 (BSL-3) pathogens or BSL-2 pathogens that mandate select agent control. The A2CD2C will enable this research using state-of-the-art equipment for small molecule (1) screening, (2) imaging, (3) liquid chromatography-mass spectrometry (LCMS/MS) services and (4) histology. The core will be housed within the UTHSC Regional Biocontainment Laboratory (RBL) in BSL-3 space. The A2CD2C is significant in that it provides an efficient, integrated, comprehensive platform that will facilitate studies from the initial discovery phase through pre-clinical development within BSL-3 containment. The A2CD2C is unique within the RBL network in its focus on providing LC-MS studies for infected, treated animal tissues in BSL-3 to provide much needed information of the site of exposure of the therapeutic at the site of infection and thereby providing important pharmacodynamic information required for preclinical assessment. The major mission of the A2CD2C is to maintain, improve and expand our RBL support services in drug discovery and development with a focus on drug pharmacodynamics in terms of how and how much drug exposure impacts pathogen survival. We propose three objectives to achieve herein: Objective 1. To maintain A2CD2C support services in drug discovery and development; Objective 2. To improve A2CD2C support services in drug discovery and development; and Objective 3. To expand A2CD2C support services in imaging in drug discovery and development.

项目摘要拟议的抗病毒和抗菌对策发现与发展核心（以下是缩写为A2CD2C）将促进针对发现和/或开发的生物医学研究人类生物安全3级（BSL-3）病原体的预防或治疗治疗的对策或 BSL-2病原体授权选择代理控制。 A2CD2C将使用最先进的小分子的设备（1）筛选，（2）成像，（3）液相色谱 - 质量光谱法（LCMS/MS）服务和（4）组织学。该核心将安置在UTHSC区域生物内在内部 BSL-3空间中的实验室（RBL）。 A2CD2C很重要，因为它提供了有效的，集成的，综合平台将促进从初始发现阶段到临床前的研究 BSL-3内的开发。 A2CD2C在RBL网络中是唯一的，重点是提供 BSL-3中受感染的，经过处理的动物组织的LC-MS研究提供了急需的信息在感染部位接触治疗性，从而提供重要的药效信息临床前评估所必需的。 A2CD2C的主要任务是维护，改善和扩展我们在药物中的RBL支持服务发现和开发的重点是在如何和多少药物上进行药物药效学暴露会影响病原体的存活。我们提出了三个目标要实现的目标：目标1。 A2CD2C在药物发现和开发中支持服务；目标2。改善A2CD2C支持服务在药物发现和开发中；和目标3。扩展药物成像中的A2CD2C支持服务发现与发展。